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Coenzyme Q is a polyisoprenylated benzoquinone lipid essential in cellular energy metabolism. Ozeir et al.
(2011) show that an enzyme, Coq6, is required for the coenzyme Q C5-ring hydroxylation, and that defects
in Coq6 can be bypassed by providing alternate ring precursors.Coenzyme Q (ubiquinone or Q) is an
essential lipid quinone in respiratory elec-
tron transport. Q accepts electrons and
protons from complex I and complex II,
and the reduced hydroquinone (QH2) is
oxidized by complex III. Q also serves as
an essential redox cofactor in the oxida-
tion of fatty acids, glycerol-3-phosphate,
dihydroorotate, sulfide, choline, and otherCO2H
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Figure 1. Many Paths to Q in Yeast
S. cerevisiae utilize 4-hydroxybenzoic acid (4-HB) and
et al., 2010). Coq2 attaches the polyisoprenyl tail (des
(HHB) and 3-hexaprenyl-4-aminobenzoic acid (HAB). T
Q6H2 (DMQ6H2) (Marbois et al., 2010). The studies of O
accumulate in yeast coq6 and yah1mutants fed pABA
can be bypassed by feeding the alternate ring precuramino acid-derived metabolites. QH2
functions as a lipid soluble chain-breaking
antioxidant, and also functions as a
coantioxidant maintaining vitamin E in its
reduced state (Turunen, et al., 2004). Yet
unlike vitamin E, QH2 is synthesized de
novo by human and other animal cells.
Studies with the yeastsSaccharomyces
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para-aminobenzoic acid (pABA) as ring precursors in
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and 4-HB, respectively (compounds denoted by red a
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Chemistry & Biology 18, September 23, 2011 ªpombe have identified many of the genes
required for Q biosynthesis (Kawamukai,
2009; Tran and Clarke, 2007). However,
the functional roles of several of the
COQ gene products (including Coq4,
Coq6, and Coq9) remain mysterious.
Previous work identified the COQ6 gene
as encoding a flavin-dependent hy-
droxylase required for synthesis of QOH
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rge at the point of 4-amino-DMQ6H2 to demethoxy-
l (4-AP) and 3-hexaprenyl-4-hydroxyphenol (4-HP)
sterisks). The coq6 or yah1 defect in Q biosynthesis
cid (VA) (compounds denoted in green).
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Figure 2. The S. cerevisiae Coq6 Monooxygenase Requires an
Additional Electron Transport System
Coq6 is shown to work in conjunction with Yah1 (ferredoxin) and Arh1 (ferre-
doxin reductase).
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Previewsin yeast (Tran and Clarke,
2007). Although the yeast
coq6 null mutant accumu-
lated 3-hexaprenyl-4-hydrox-
ybenzoic acid (HHB) (Fig-
ure 1), this same early
intermediate was found to
accumulate in each of the
coq null mutants (coq3–
coq9), and thus was not diag-
nostic of the blocked step
(Tran and Clarke, 2007).
Many of the yeast coq null
mutants (including the coq6
null mutant) were shown to
lack other Coq polypeptide
partner proteins, due to the
destabilization of a large Coqpolypeptide complex required for Q
biosynthesis.
In this issue, Ozeir et al. (2011) identify
the function of the Coq6 polypeptide as
required for the C5-hydroxylation in yeast
coenzyme Q biosynthesis. The authors
use a combination of yeast genetics, lipid
biochemistry, and clever feeding experi-
ments of alternate ring precursors to
characterize the defective step in yeast
coq6 mutants. The authors capitalize on
the observations that several of the yeast
coq null mutants harboring multicopy
COQ8 have restored steady state levels
of the Coq3 and Coq4 polypeptides
(Zampol, et al., 2010), and, in the case of
the coq7 null, accumulate DMQ6, an inter-
mediate just two steps removed from Q
(Padilla, et al., 2009). Ozeir et al. (2011)
show: (1) the yeast coq6 null mutants
harboring the COQ8 gene on a multicopy
plasmid produce intermediates lacking
the C5-ring hydroxyl group; and (2) yeast
coq6 null mutants expressing inactive
Coq6p with two amino acid substitution
mutations (Coq6-G386A,N388D) also
accumulate the same two intermediates
lacking the C5-ring hydroxyl, namely,
3-hexaprenyl-4-aminophenol (4-AP) and
3-hexaprenyl-4-hydroxyphenol (4-HP)
(Figure 1). These intermediates are
shown to accumulate when the yeast are
supplied with either para-aminobenzoic
acid (pABA) or 4-hydroxybenzoic acid
(4-HB) as the respective aromatic ring
precursors.
The authors identified 4-AP and 4-HP
previously, and showed that they accu-
mulate in two other yeast mutants defi-
cient in either ferredoxin (Yah1) or ferre-
doxin reductase (Arh1) (Pierrel et al.,1070 Chemistry & Biology 18, September 23,2010). In the present study, the coq6-,
yah1-, arh1-, and flx1 (FLX1 encodes a
mitochondrial FAD transporter)- deficient
yeast mutants are connected by their
identical accumulation of 4-AP and
4-HB. Thus, unlike most flavin-dependent
monooxygenases, the electrons from
NADPH are funneled indirectly to yeast
Coq6 via ferredoxin reductase and ferre-
doxin (Figure 2).
The tour de force of the study are
the bypass feeding experiments, where
alternate aromatic ring precursors are
supplied that rescue the yah1 deficient
mutant and the coq6 null mutant har-
boring multicopy COQ8. These precur-
sors include 3,4-dihydroxy-benzoic acid
(3,4-diHB) and vanillic acid (VA) (Figure 1).
By supplying either of these precursors,
the authors demonstrate that the coq6
and yah1 deficient yeast mutants now
acquire the ability to grow on nonferment-
able carbon source and synthesize Q6.
These bypass experiments convincingly
demonstrate that the defect in Q biosyn-
thesis in the coq6 yeast mutant is due to
the lack of C5-ring hydroxylation.
A recent report identified Q deficiencies
in patients with mutations in the human
homolog of Coq6 (Heeringa et al., 2011).
Expression of the human Coq6 polypep-
tide in yeast coq6 null mutants was
shown to rescue growth on nonferment-
able carbon source and to restore syn-
thesis of Q6. Together with the findings
of Ozeir et al. (2011), these results indi-
cate that both human and yeast Coq6p
function at the C5-ring hydroxylation
step. In a prescient review discussing
potential alternate pathways of coenzyme
Q biosynthesis, Olson and Rudney (1983)2011 ª2011 Elsevier Ltd All rights reservednoted that 3,4-diHB and VA
could supply ring precursors
for prenylation via metabo-
lism of tyrosine and norepi-
nephrine. Now, as suggested
by Ozeir et al. (2011), it is
possible that the deficiency
in Q biosynthesis in certain
human patients could be cor-
rected by administering such
alternate ring precursors.
The use of pABA by human
or animal cells as a metabolic
precursor in Q biosynthesis
is possible, but so far has
not been shown experimen-
tally. It will be interesting
to determine whether theCoq6-defective patient-derived cells or
cell lines accumulate 4-AP or 4-HP as
Q intermediates. It is not yet known
whether 4-AP and/or 4-HP are productive
Q intermediates. If so, then not only are
there multiple pathways to Q, but these
pathways may be branched, with flexi-
bility in the metabolic sequence of steps
similar to that of bile acid synthesis.REFERENCES
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